Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Blincyto

(blin-SY-toh)
A drug used to treat adults and children aged 1 month and older with certain types of B-cell acute lymphoblastic leukemia that are CD19 positive (expresses the protein CD19). It is also being studied in the treatment of other types of cancer. Blincyto binds to CD19, which is found on most B cells (a type of white blood cell) and some types of leukemia cells. It also binds to a protein called CD3, which is found on T cells (another type of white blood cell). This may help the immune system kill cancer cells. Blincyto is a type of bispecific T-cell engager. Also called blinatumomab.
More Information
Search NCI's Dictionary of Cancer Terms